Addressing COVID-19 Testing Disparities in Vulnerable Populations Using a Community JITAI (Just in Time Adaptive Intervention) Approach - Phase II
Project Number3UL1TR003167-03S3
Former Number3UL1TR003167-02S6
Contact PI/Project LeaderMCPHERSON, DAVID D Other PIs
Awardee OrganizationUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
Description
Abstract Text
ABSTRACT
The
(Phase
goal of the Center for Clinical and Translational Science's (CCTS) proposed continuation
II) RADx-UP 121 project is todetermine trends and disparities of SARS-CoV-2 testing,
infections, and COVID-19 vaccination coverage in threetargeted Texas regions:Houston/Harris
County; South Texas (Cameron and Hidalgo Counties; and 3) Northeast TX (seven counties
including the city of Tyler). This effort will result in improved and expanded
time
related
will:
recent
structural
and
access
enabled
multilevel, just-in-
adaptive intervention trategies to reach vulnerable populations experiencing inequities
to COVID-19. More specifically, in collaboration with community partners, this project
1) identify disparities and dynamics of SARS-CoV-2 testing and infections, considering
data on COVID-19 vaccination; 2) identify personal, organizational, community, and
factors contributing to SARS-CoV-2 testing and COVID-19 vaccination disparities,
3) expand the reach and impact of a
multil evel intervention to increase motivation for and
to testing and vaccination among vulnerable populations. The project's efforts will be
by leveraging long-standing community partnerships.
s
Phase II will be informed by learnings and accomplishments from the Phase I effort,
which have included: (1) Developing real-time data processing procedures and implemented
quality control measures for various local data, including SARS-CoV-2 testing data, case
investigation and hospital records; (2) Processing and analyzing COVID-19 case data including
over 367,000 cases in Harris County, over 40,000 in Cameron County, and over 29,000 cases in
Northeast Texas counties - all datasets now have common data elements and consistent formats;
(3) Developing several metrics to quantify the COVID-19 disease burden for the overall
population and by demographic subgroups; (4) Developing the census block group (CBG)-level
disparity index, which is constructed using 12 variables from the American Community Survey
(ACS) and; (5) Identifying the CBGs disproportionately affected by SARS-CoV-2 infections and
prioritizing them for interventions to increase testing uptake and COVID-19 vaccination using
the developed disease burden metrics and disparity index.
Changes (enhancements and expansion) to be implemented in Phase II, as compared to
Phase I (benchmark), include: (A) Adapting Phase I CHW-training/outreach program to include
training on motivational interviewing, and an expanded focus on vaccination education and
motivation/promotion of testing; (B) Enhancing 2-1-1-based education, motivation, and referral
to testing and vaccination, (C) Including broader-based social media outreach, such as geo-
targeted Facebook ads to motivate users to access COVID-19 testing and vaccination; (D)
Conducting a panel study to compare the effectiveness of the CHW-Facilitated Self-Sampling
Intervention vs. CHW Testing Navigation Intervention on participation in SARS-CoV-2 testing,
and; (E) Assessing the impact and reach of multilevel COVID-19 communication networks on
individuals' attitudes, intentions, and decisions on behavior surrounding SARS-CoV-2 testing
and COVID-19 vaccination in underserved communities.
Public Health Relevance Statement
Narrative:
This study will leverage long-standing academic-community partnerships to examine COVID-19
infection, testing, and vaccination patterns in three Texas regions (Houston/Harris County,
South Texas, and Northeast Texas) to identify underserved communities. In these communities,
we will provide and evaluate a multilevel intervention to increase reach, uptake,
implementation, and sustainment of SARS-CoV-2 testing and COVID-19 vaccination. We will
also explore the impact and reach of people's communication networks on attitudes, intentions,
and decisions on behavior regarding SARS-CoV-2 testing and COVID-19 vaccination.
National Center for Advancing Translational Sciences
CFDA Code
350
DUNS Number
800771594
UEI
ZUFBNVZ587D4
Project Start Date
17-September-2021
Project End Date
30-June-2023
Budget Start Date
17-September-2021
Budget End Date
30-June-2022
Project Funding Information for 2021
Total Funding
$1,174,131
Direct Costs
$796,433
Indirect Costs
$377,698
Year
Funding IC
FY Total Cost by IC
2021
NIH Office of the Director
$1,174,131
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3UL1TR003167-03S3
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3UL1TR003167-03S3
Patents
No Patents information available for 3UL1TR003167-03S3
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3UL1TR003167-03S3
Clinical Studies
No Clinical Studies information available for 3UL1TR003167-03S3
News and More
Related News Releases
No news release information available for 3UL1TR003167-03S3
History
No Historical information available for 3UL1TR003167-03S3
Similar Projects
No Similar Projects information available for 3UL1TR003167-03S3